{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T07:59:18Z","timestamp":1789545558372,"version":"build-2803163510"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome, a rare autoinflammatory disease, is usually defined by musculoskeletal symptoms and cutaneous manifestations. Cutaneous manifestations include palmoplantar pustulosis or severe acne, which are generally accompanied by osteitis and hyperostosis, and are the hallmark of SAPHO syndrome. Genetic, immune, and microbial factors are involved in the pathophysiology of the SAPHO. Small-molecule targeted therapies and biologic agents have transformed the treatment of inflammatory disorders. Upadacitinib, with efficacy in cytokine-related disorders, represents a therapeutic candidate for SAPHO syndrome. Here we report a patient with a 20-year history of pustular palmoplantar psoriasis (PPP) who developed progressive inflammatory arthralgia over the past decade. Radiographic and scintigraphic evaluations showed distinct sternocostoclavicular hyperostosis and osteitis, confirming a diagnosis of SAPHO syndrome. Conventional therapies, including nonsteroidal anti-inflammatory drugs (NSAIDs), disease-modifying antirheumatic drugs (DMARDs), and topical agents, failed to improve cutaneous or articular symptoms. After ineffective treatment with secukinumab (an IL-17A inhibitor), transitioning to upadacitinib (a selective JAK1 inhibitor) improved pustular lesions and reduced joint pain and inflammation, demonstrating clinical improvement. This case illustrates the effectiveness of upadacitinib, a selective JAK1 inhibitor, for the rapid resolution of cutaneous and articular symptoms of SAPHO syndrome following unsuccessful IL-17A inhibition, offering valuable insights for management of refractory SAPHO syndrome.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1662675","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T06:23:13Z","timestamp":1763446993000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Upadacitinib in the treatment of SAPHO syndrome: a case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Yanran","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanxue","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongpeng","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/s0950-3579(94)80022-7","article-title":"The SAPHO syndrome","volume":"8","author":"Kahn","year":"1994","journal-title":"Baillieres Clin Rheumatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2012.05.006","article-title":"The SAPHO syndrome","volume":"42","author":"Nguyen","year":"2012","journal-title":"Semin Arthritis Rheum"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003688","article-title":"Treatment and monitoring of SAPHO syndrome: A systematic review","volume":"9","author":"Li","year":"2023","journal-title":"RMD Open"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2018.04.003","article-title":"Biologics in SAPHO syndrome: A systematic review","volume":"48","author":"Daoussis","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.3390\/jcm14041366","article-title":"What is new and what is next for SAPHO syndrome management: A narrative review","volume":"14","author":"Ferraioli","year":"2025","journal-title":"J\u00a0Clin Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185x.14774","article-title":"Novel JAK-1 inhibitor upadacitinib as a possible treatment for refractory SAPHO syndrome: A case report","volume":"26","author":"Ma","year":"2023","journal-title":"Int J Rheum Dis"},{"key":"B7","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s41927-018-0031-x","article-title":"In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (Abt-494)","volume":"2","author":"Parmentier","year":"2018","journal-title":"BMC Rheumatol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAt signaling pathway: from bench to clinic","volume":"6","author":"Hu","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1427784","article-title":"The role of cytokines in the pathogenesis of SAPHO syndrome","volume":"15","author":"Yang","year":"2024","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2006.06.006","article-title":"Valuable lessons from SAPHO syndrome","volume":"74","author":"Hayem","year":"2007","journal-title":"Joint Bone Spine"},{"key":"B11","article-title":"Synovitis-acne-pustulosis-hyperostosis-osteitis (SAPHO) syndrome","volume":"115","author":"Benhamou","year":"1988","journal-title":"Ann Dermatol Venereol"},{"key":"B12","article-title":"SAPHO syndrome","volume":"54","author":"Hayem","year":"2004","journal-title":"Rev Prat"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0b013e31819a205c","article-title":"F-18 FDG PET\/CT can help differentiate SAPHO syndrome from suspected metastatic bone disease","volume":"34","author":"Patel","year":"2009","journal-title":"Clin Nucl Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.20452\/pamw.4261","article-title":"Clinical symptoms, imaging, and treatment of SAPHO syndrome: A single\u2212Center study of 52 cases","volume":"128","author":"Przepiera-B\u0119dzak","year":"2018","journal-title":"Pol Arch Intern Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/s0049-0172(99)80027-4","article-title":"SAPHO syndrome: A long-term follow-up study of 120 cases","volume":"29","author":"Hayem","year":"1999","journal-title":"Semin Arthritis Rheum"},{"key":"B16","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/jdv.13846","article-title":"What do we know about palmoplantar pustulosis","volume":"31","author":"Misiak-Galazka","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199810)41:10<1889::Aid-art23>3.0.Co;2-f","article-title":"Propionibacterium acnes isolated from synovial tissue and fluid in a patient with oligoarthritis associated with acne and pustulosis","volume":"41","author":"Schaeverbeke","year":"1998","journal-title":"Arthritis Rheum"},{"key":"B18","article-title":"Propionibacterium acnes isolated from sternal osteitis in a patient with SAPHO syndrome","volume":"23","author":"Kotilainen","year":"1996","journal-title":"J Rheumatol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2017.04.010","article-title":"SAPHO, autophagy, IL-1, FoxO1, and propionibacterium (Cutibacterium) acnes","volume":"85","author":"Berthelot","year":"2018","journal-title":"Joint Bone Spine"},{"key":"B20","article-title":"Propionibacterium acnes and SAPHO syndrome: A case report and literature review","volume":"25","author":"Colina","year":"2007","journal-title":"Clin Exp Rheumatol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3109\/08916934.2014.906582","article-title":"Th17 cells are increased in the peripheral blood of patients with SAPHO syndrome","volume":"47","author":"Firinu","year":"2014","journal-title":"Autoimmunity"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17081255","article-title":"Serum interleukin-18, fetuin-a, soluble intercellular adhesion molecule-1, and endothelin-1 in ankylosing spondylitis, psoriatic arthritis, and SAPHO syndrome","volume":"17","author":"Przepiera-B\u0119dzak","year":"2016","journal-title":"Int J Mol Sci"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e328363eb08","article-title":"Autoinflammatory bone disorders: update on immunologic abnormalities and clues about possible triggers","volume":"25","author":"Sharma","year":"2013","journal-title":"Curr Opin Rheumatol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e21541","article-title":"Family aggregation and prevalence of other autoimmune diseases in SAPHO syndrome","volume":"9","author":"Li","year":"2023","journal-title":"Heliyon"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.643644","article-title":"Genome-wide association identifies risk pathways for SAPHO syndrome","volume":"9","author":"Cai","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1560398","article-title":"Therapeutic approaches for SAPHO syndrome from the perspective of pathogenesis: A review of the literature","volume":"16","author":"Wang","year":"2025","journal-title":"Front Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1177\/1759720x20912865","article-title":"Synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome: review and update","volume":"12","author":"Liu","year":"2020","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2021.115887","article-title":"Bisphosphonates in inflammatory rheumatic diseases","volume":"146","author":"Peris","year":"2021","journal-title":"Bone"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2012.03.012","article-title":"Intra-articular glucocorticosteroid injection into sternocostoclavicular joints in patients with SAPHO syndrome","volume":"42","author":"Jung","year":"2012","journal-title":"Semin Arthritis Rheum"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.140342","article-title":"The SAPHO syndrome: A single-center study of 41 adult patients","volume":"42","author":"Aljuhani","year":"2015","journal-title":"J Rheumatol"},{"key":"B31","article-title":"Biologics for rare inflammatory diseases: TNF blockade in the SA PHO syndrome","volume":"70","author":"Burgemeister","year":"2012","journal-title":"Neth J Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.2147\/ccid.S446468","article-title":"Successful treatment of refractory synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome with baricitinib, a janus kinase inhibitor","volume":"17","author":"Yang","year":"2024","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"e66169","DOI":"10.7759\/cureus.66169","article-title":"Successful treatment of refractory synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome with tofacitinib: A case report","volume":"16","author":"Alhayali","year":"2024","journal-title":"Cureus"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2023.2207737","article-title":"Recent developments for new investigational JAK inhibitors in psoriatic arthritis","volume":"32","author":"Caso","year":"2023","journal-title":"Expert Opin Investig Drugs"},{"key":"B35","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s40265-023-01840-5","article-title":"Safety of janus kinase inhibitors in inflammatory bowel diseases","volume":"83","author":"N\u00fa\u00f1ez","year":"2023","journal-title":"Drugs"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-024-00671-4","article-title":"Safety profile of upadacitinib up to 5 years in psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis: an integrated analysis of clinical trials","volume":"11","author":"Burmester","year":"2024","journal-title":"Rheumatol Ther"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-223916","article-title":"Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the select phase iii rheumatoid arthritis clinical programme","volume":"82","author":"Fleischmann","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-025-03328-y","article-title":"Safety profile of upadacitinib: descriptive analysis in over 27,000 patient-years across rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, atopic dermatitis, and inflammatory bowel disease","volume":"42","author":"Burmester","year":"2025","journal-title":"Adv Ther"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.3095","article-title":"Tofacitinib for the treatment of nail lesions and palmoplantar pustulosis in synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome","volume":"157","author":"Li","year":"2021","journal-title":"JAMA Dermatol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"e11149","DOI":"10.1097\/md.0000000000011149","article-title":"Case report: successful treatment of refractory sapho syndrome with the JAK inhibitor tofacitinib","volume":"97","author":"Yang","year":"2018","journal-title":"Med (Baltimore)"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1155\/2023\/6201887","article-title":"A case of SAPHO syndrome complicated by uveitis with good response to both TNF inhibitor and JAKinib","volume":"2023","author":"Baisya","year":"2023","journal-title":"Case Rep Rheumatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1662675\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T06:23:14Z","timestamp":1763446994000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1662675\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,18]]},"references-count":41,"alternative-id":["10.3389\/fimmu.2025.1662675"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1662675","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,18]]},"article-number":"1662675"}}